Sign In
Buy AYTU
$2.09
-0.0100 (-0.476%)
At Close: Jun 03, 2026
Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
04:15pm, Monday, 01'st Jun 2026
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervo
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
04:05pm, Monday, 18'th May 2026
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervo
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
09:30pm, Wednesday, 13'th May 2026
Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 13'th May 2026
Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.2 per share a year ago.
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
04:05pm, Wednesday, 13'th May 2026
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth rates Total net revenue of $12.4 millio
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
04:05pm, Wednesday, 06'th May 2026
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervou
Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Analysts
03:32am, Monday, 16'th Feb 2026
Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have received a consensus rating of "Hold" from the five brokerages that are covering the stock, MarketBeat Ratings reports. Two equities
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
08:00pm, Tuesday, 03'rd Feb 2026
Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
07:15pm, Tuesday, 03'rd Feb 2026
Aytu BioPharma Inc. (AYTU) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.28 per share a year ago.
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
04:05pm, Tuesday, 03'rd Feb 2026
Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) exte
New Strong Sell Stocks for February 2nd
06:40am, Monday, 02'nd Feb 2026
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
04:05pm, Tuesday, 27'th Jan 2026
DENVER, CO / ACCESS Newswire / January 27, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Recommendation of “Hold” by Brokerages
04:41am, Thursday, 22'nd Jan 2026
Shares of Aytu BioPharma Inc. (NASDAQ: AYTU - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat Rat
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
08:05pm, Tuesday, 20'th Jan 2026
Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
04:05pm, Tuesday, 20'th Jan 2026
DENVER, CO / ACCESS Newswire / January 20, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central n
